Literature DB >> 16297286

Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment.

W Apt1, A Arribada, I Zulantay, A Solari, G Sánchez, K Mundaca, X Coronado, J Rodríguez, L C Gil, A Osuna.   

Abstract

Eleven years after they had been given itraconazole or allopurinol for the treatment of chronic American trypanosomiasis, 109 adult patients were checked for electrocardiographic abnormalities and evidence of Trypanosoma cruzi infection. The parasitological investigations included xenodiagnosis, in which the faeces of Triatoma infestans that had fed on the patients were checked under the microscope for flagellates. In addition, a PCR-based assay and a hybridization assay were used to test blood samples from the patients, and faeces from the Tri. infestans that had fed on the patients, for Try. cruzi DNA. For the data analysis, the patients were divided into four groups known as normal/normal, abnormal/normal, normal/abnormal and abnormal/abnormal, according to whether the patients had been found to have normal or abnormal electrocardiograms (ECG) shortly before the first treatment and to have normal or abnormal ECG when checked at the 11-year follow-up. The 51 normal/normal and 24 normal/abnormal patients were assumed to have been in the 'indeterminate' phase of the disease when they were treated, whereas the 16 abnormal/normal and 18 abnormal/abnormal patients all had evidence of chagasic cardiopathy at that time. When checked 11 years post-treatment, 40 (78.4%), 17 (70.8%), 14 (87.5%) and 17 (94.4%) of these patients, respectively, were each found positive for Try. cruzi in at least one of the parasitological tests. The hybridization assay, whether applied to human blood or bug faeces, appeared a significantly more sensitive test than the PCR-based assays or microscopically assessed xenodiagnosis (P<0.05). Only the 21 patients who appeared to be negative for Try. cruzi could be considered parasitologically cured (although all still appeared to have anti-Try. cruzi antibodies in their blood). Only 13 of these parasitologically cured patients (seven of those treated with itraconazole and six of those given allopurinol) had normal ECG at the 11-year follow-up. In Chile at least, itraconazole, which caused fewer adverse effects than the allopurinol while being no less effective at preventing cardiopathy, appears to be the drug of choice to treat chronic American trypanosomiasis in adults.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16297286     DOI: 10.1179/136485905X75403

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  14 in total

1.  Mannose-binding lectin and Toll-like receptor polymorphisms and Chagas disease in Chile.

Authors:  Thomas Weitzel; Inés Zulantay; Ina Danquah; Lutz Hamann; Ralf R Schumann; Werner Apt; Frank P Mockenhaupt
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

2.  Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy.

Authors:  Susana A Laucella; Damián Pérez Mazliah; Graciela Bertocchi; María G Alvarez; Gretchen Cooley; Rodolfo Viotti; María C Albareda; Bruno Lococo; Miriam Postan; Alejandro Armenti; Rick L Tarleton
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

Review 3.  Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection.

Authors:  Juan Carlos Villar; Juan Guillermo Perez; Olga Lucia Cortes; Adelina Riarte; Micah Pepper; Jose Antonio Marin-Neto; Gordon H Guyatt
Journal:  Cochrane Database Syst Rev       Date:  2014-05-27

4.  Trypanosoma cruzi: biological characterization of a isolate from an endemic area and its susceptibility to conventional drugs.

Authors:  Noelia L Grosso; Jacqueline Bua; Alina E Perrone; Mariela N Gonzalez; Patricia L Bustos; Miriam Postan; Laura E Fichera
Journal:  Exp Parasitol       Date:  2010-05-21       Impact factor: 2.011

5.  Antitrypanosomal activity of Senna villosa in infected BALB/c mice with Trypanosoma cruzi during the sub acute phase of infection.

Authors:  Matilde Jimenez-Coello; Eugenia Guzman-Marin; Salud Perez-Gutierrez; Glendy Marilu Polanco-Hernandez; Karla Yolanda Acosta-Viana
Journal:  Afr J Tradit Complement Altern Med       Date:  2011-07-03

6.  Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.

Authors:  D E Perez-Mazliah; M G Alvarez; G Cooley; B E Lococo; G Bertocchi; M Petti; M C Albareda; A H Armenti; R L Tarleton; S A Laucella; R Viotti
Journal:  J Antimicrob Chemother       Date:  2012-10-26       Impact factor: 5.790

7.  A Combination of Itraconazole and Amiodarone Is Highly Effective against Trypanosoma cruzi Infection of Human Stem Cell-Derived Cardiomyocytes.

Authors:  Gabriele Sass; Roy T Madigan; Lydia-Marie Joubert; Adriana Bozzi; Nazish Sayed; Joseph C Wu; David A Stevens
Journal:  Am J Trop Med Hyg       Date:  2019-08       Impact factor: 2.345

Review 8.  Current and developing therapeutic agents in the treatment of Chagas disease.

Authors:  Werner Apt
Journal:  Drug Des Devel Ther       Date:  2010-09-24       Impact factor: 4.162

9.  Allopurinol reduces antigen-specific and polyclonal activation of human T cells.

Authors:  Damián Pérez-Mazliah; María C Albareda; María G Alvarez; Bruno Lococo; Graciela L Bertocchi; Marcos Petti; Rodolfo J Viotti; Susana A Laucella
Journal:  Front Immunol       Date:  2012-09-21       Impact factor: 7.561

10.  The epidemiological relevance of family study in Chagas disease.

Authors:  Inés Zulantay; Werner Apt; Daniel Ramos; Lorena Godoy; Claudio Valencia; Matías Molina; Eduardo Sepúlveda; Patricio Thieme; Gabriela Martínez; Gabriela Corral
Journal:  PLoS Negl Trop Dis       Date:  2013-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.